Evidence map›Paper›PMID 38629075›Full record

ReviewFrontiers in immunology2024

Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.

Cristián Gutiérrez-Vera, Richard García-Betancourt, Pablo A Palacios, Marioly Müller, David A Montero, Carlos Verdugo, Francisca Ortiz, Felipe Simon, Alexis M Kalergis, Pablo A González and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Multifaceted roles of mitochondria in asthma.Cell biology and toxicology · 2024
    Review
  10. Review
  11. CAR-NKT Cells in Asthma: Use of NKT as a Promising Cell for CAR Therapy.Clinical reviews in allergy & immunology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Cristián Gutiérrez-VeraMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Richard García-BetancourtMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Pablo A PalaciosMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Marioly MüllerDepartamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
David A MonteroMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Carlos VerdugoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Francisca OrtizMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Felipe SimonMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Alexis M KalergisMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Pablo A GonzálezMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Noemi A Saavedra-AvilaDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Steven A PorcelliDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States.
Leandro J CarreñoMillennium Institute on Immunology and Immunotherapy, Santiago, Chile.
Millennium Institute on Immunology and Immunotherapy · CLUniversity of Chile · CLAlbert Einstein College of Medicine · USUniversidad Andrés Bello · CL

Funding

Precision Targeting of CD1-Restricted iNKT Cells for Cancer ImmunotherapyR01AI045889 · NIAID · YESHIVA UNIVERSITY · PI Steven A Porcelli · 1999 to 2026
$9.3M
Harnessing NKT Cell Activation by GlycolipidsR01GM111849 · NIGMS · UNIVERSITY OF CONNECTICUT STORRS · PI HOWELL, AMY · 2019 to 2022
$2.1M
Harnessing NKT Cell Activation by GlycolipidsU01GM111849 · NIGMS · UNIVERSITY OF CONNECTICUT STORRS · PI HOWELL, AMY · 2014 to 2017
$1.9M
NIAID NIH HHS R01 AI045889NIGMS NIH HHS R01 GM111849NIGMS NIH HHS U01 GM111849
6 · The paper itself

Abstract

Allergic asthma has emerged as a prevalent allergic disease worldwide, affecting most prominently both young individuals and lower-income populations in developing and developed countries. To devise effective and curative immunotherapy, it is crucial to comprehend the intricate nature of this condition, characterized by an immune response imbalance that favors a proinflammatory profile orchestrated by diverse subsets of immune cells. Although the involvement of Natural Killer T (NKT) cells in asthma pathology is frequently implied, their specific contributions to disease onset and progression remain incompletely understood. Given their remarkable ability to modulate the immune response through the rapid secretion of various cytokines, NKT cells represent a promising target for the development of effective immunotherapy against allergic asthma. This review provides a comprehensive summary of the current understanding of NKT cells in the context of allergic asthma, along with novel therapeutic approaches that leverage the functional response of these cells.

Indexed as

AsthmaHypersensitivityNatural Killer T-CellsCytokinesHumansImmunotherapyCytokinesallergic diseasesasthmaimmunomodulationimmunotherapynatural killer T cells

Identifiers

PMID38629075
PMCPMC11018981
OpenAlexW4393442687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.